hormone therapy
- Generic Name
- hormone therapy
New Insights on Diet and Exercise Impacting Prostate Cancer Outcomes Revealed at PCF Scientific Retreat
The 31st Annual PCF Scientific Retreat highlighted significant advancements in understanding how diet and exercise can influence prostate cancer outcomes. Key findings suggest that a plant-based diet and regular physical activity can improve survivorship and reduce mortality rates. Ongoing clinical trials, such as INTERVAL-GAP4 and Prostate-8-II, aim to further explore these interventions' effects on patients with prostate cancer.
OPTIMA Trial Explores Predictive Test for Chemotherapy in Breast Cancer Treatment
The OPTIMA trial investigates the use of the Prosigna test to predict which breast cancer patients may benefit from chemotherapy, aiming to personalize treatment plans. This phase 3 trial involves 4,500 participants and compares outcomes between standard chemotherapy and hormone therapy versus treatment guided by the Prosigna test. The study also evaluates the impact on patients' quality of life over time.
SBRT Shows Non-Inferiority to Standard Radiotherapy in Localized Prostate Cancer
• A phase 3 trial, PACE-B, reveals that five-fraction stereotactic body radiotherapy (SBRT) is non-inferior to conventional radiotherapy for low- to intermediate-risk localized prostate cancer.
• The 5-year incidence of freedom from biochemical or clinical failure was 95.8% in the SBRT group and 94.6% in the control group, indicating comparable cancer control outcomes.
• SBRT offers a reduced treatment duration, potentially alleviating the burden on healthcare systems while maintaining favorable cancer control without hormonal treatment.
• While genitourinary adverse effects were slightly higher in the SBRT group, the overall safety profile was acceptable, supporting SBRT as a viable alternative to standard radiotherapy.
Avutometinib and Defactinib Show Promise in Recurrent Low-Grade Serous Ovarian Cancer
• Updated data from the RAMP 201 trial shows the combination of avutometinib and defactinib yields robust responses in recurrent low-grade serous ovarian cancer (LGSOC).
• The combination therapy demonstrated an overall response rate of 31% in all evaluable patients and 44% in those with KRAS-mutated LGSOC.
• Verastem Oncology is on track to complete its NDA submission to the FDA in October 2024, seeking accelerated approval for KRAS-mutant LGSOC.
• A phase 3 trial, RAMP 301, is underway to confirm these findings and potentially expand the treatment's indication regardless of KRAS mutation status.
MSK Research: CDK2 Inhibition Overcomes Breast Cancer Drug Resistance, 177Lu-PSMA-617 Shows Promise in Prostate Cancer
• Researchers identified that mutations in the p53 gene are associated with resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer, and CDK2 inhibition may overcome this resistance.
• A Phase 3 trial indicates that 177Lu-PSMA-617 (Pluvicto®) improves disease control and quality of life in metastatic castration-resistant prostate cancer patients compared to second-line hormonal therapies.
• Updated guidelines based on a study of over 1,400 patients provide insights into optimal SBRT dosing for spinal metastasis to minimize the risk of radiation myelitis.
• A phase 2 clinical trial demonstrates that proton therapy can effectively halt the progression of recurrent head and neck cancers previously treated with radiation, offering a less toxic alternative.
Datopotamab Deruxtecan Shows Promise in Advanced Gynecologic Cancers
• Datopotamab deruxtecan (Dato-DXd) demonstrates encouraging antitumor activity in patients with advanced ovarian cancer post-platinum chemotherapy.
• In endometrial cancer, Dato-DXd showed a confirmed objective response rate of 27.5% with a median duration of response of 16.4 months.
• The TROPION-PanTumor03 study indicates Dato-DXd has a manageable safety profile, with mostly low-grade stomatitis and nausea reported.
• These findings suggest Dato-DXd could be a potential treatment option for patients with limited alternatives after platinum-based therapies.
Patritumab Deruxtecan Shows Promise in HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor Resistance
• Patritumab deruxtecan (HER3-DXd) demonstrates a 53.5% response rate in heavily pre-treated HR+/HER2- metastatic breast cancer patients resistant to CDK4/6 inhibitors.
• The ICARUS-BREAST01 phase II trial reports a median progression-free survival of 9.4 months with patritumab deruxtecan, suggesting improved outcomes compared to conventional third-line chemotherapies.
• Researchers identified potential factors influencing treatment response, including the distribution of HER3-positive cells within the tumor and drug-induced immune response.
• Patritumab deruxtecan may represent a new therapeutic option for advanced hormone-dependent breast cancer, warranting further investigation in larger studies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath